Study #2022-0476
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
EP0031
Description
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Physician name:
Yasir Elamin
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.